| Similar Articles |
|---|
 |
The Motley Fool
July 25, 2007
Brian Orelli |
On to the FDA With a New Name After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application for ferumoxytol, and if all goes well, could have the product on the market by the end of next year.   |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
June 30, 2009
Brian Orelli |
One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days. |
The Motley Fool
August 13, 2008
Brian Orelli |
The Good and Bad of 3SBio Chinese biotech 3SBio is still trading well below its IPO price from last year and its second-quarter earnings release isn't going to help it much. But investors willing to take a risk will likely do OK. |
The Motley Fool
July 21, 2011
Brian Orelli |
AMAG-Allos, a Match Made in Necessity What do you get when you combine one unprofitable biotech, AMAG Pharmaceuticals, with another unprofitable biotech, Allos Therapeutics? |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
American Family Physician
October 15, 2002
Mahesh Krishnan |
Preoperative Care of Patients with Kidney Disease Preoperative attention to common medical problems that occur in patients with impaired renal function can lower some surgical risks. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Chemistry World
December 6, 2012
Andrew Turley |
Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion |
The Motley Fool
January 26, 2009
Brian Orelli |
Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
InternetNews
June 3, 2010 |
UofL Web Site Exposes Patients' Personal Info A doctor at the University of Louisville Hospital set up an internal Web site and data base to track and monitor kidney dialysis patients. The problem is the site wasn't password protected. |
Chemistry World
September 30, 2014
Phillip Broadwith |
Lumara splits and sells to AMAG and Perrigo Women's health specialist Lumara is to be split in two and sold to AMAG and consumer healthcare firm Perrigo. |
Pharmaceutical Executive
October 1, 2010 |
Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives. |
